Valuation: Artiva Biotherapeutics, Inc.

Market Cap 436M 377M 357M 323M 606M 41.79B 611M 4.26B 1.64B 21.19B 1.64B 1.6B 67.57B P/E 2026 *
-3.44x
P/E 2027 * -3.29x
Enterprise Value 436M 377M 357M 323M 606M 41.79B 611M 4.26B 1.64B 21.19B 1.64B 1.6B 67.57B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.27%
Yield 2026 *
-
Yield 2027 * -
1 day-12.13%
1 week-18.11%
Current month-21.15%
1 month-22.18%
3 months-2.94%
6 months+44.17%
Current year+107.69%
1 week 8.84
Extreme 8.84
10.93
1 month 8.84
Extreme 8.84
12.08
Current year 3.62
Extreme 3.62
14.53
1 year 2.22
Extreme 2.22
14.53
3 years 1.47
Extreme 1.47
17.31
5 years 1.47
Extreme 1.47
17.31
10 years 1.47
Extreme 1.47
17.31
Manager TitleAgeSince
Chief Executive Officer 51 05/01/2021
President 63 18/05/2026
Chief Tech/Sci/R&D Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 40 01/06/2020
Director/Board Member 51 05/01/2021
Chairman 67 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Free

Chairperson

180,000 0.3682%
09/09/26 Free

Chief Technology Officer

160,000 0.3273%
09/09/26 Free

Compliance Officer

180,000 0.3682%
Change 5-day change 1-year change 3-year change Capi.($)
-12.13%-18.11%+279.15% - 436M
+0.56%-3.38%-1.83%+8.00% 45.81B
-0.12%-1.19%+343.42%+545.03% 43.91B
+1.51%+4.04%+45.01%+27.38% 44.39B
-2.07%-1.42%+4.28%+72.97% 39.4B
-0.73%-3.06%+9.63%+38.92% 31.26B
-9.49%-11.23% - - 15.75B
+4.21%+5.01%+24.99%+121.62% 17.32B
+1.83%+3.20%+16.49%+32.73% 14.73B
-0.08%-2.81%+79.24%+31.27% 13.03B
Average -1.65%-2.02%+88.93%+109.74% 26.6B
Weighted average by Cap. -0.27%-1.24%+77.09%+130.49%

Financials

2026 *2027 *
Net sales - -
Net income -107M -92.68M -87.63M -79.34M -149M -10.26B -150M -1.05B -402M -5.2B -402M -393M -16.6B -135M -117M -111M -100M -188M -12.98B -190M -1.32B -509M -6.58B -508M -497M -20.98B
Net Debt - -
Logo Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Employees
115
Date Price Change Volume
15/09/26 $8.910 -12.13% 584,582
14/09/26 $10.14 -0.78% 243,866
11/09/26 $10.22 -1.92% 228,437
10/09/26 $10.42 -3.43% 449,476
09/09/26 $10.79 -0.83% 325,338
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.910USD
Average target price
35.80USD
Spread / Average Target
+301.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARTV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!